FR901228A
(en)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Ring gap magnet system
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
DE69233482T2
(en)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
ATE255131T1
(en)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
HUMANIZED HEREGULIN ANTIBODIES
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
WO1993007105A1
(en)
|
1991-10-04 |
1993-04-15 |
Iit Research Institute |
Conversion of plastic waste to useful oils
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
ES2202310T3
(en)
|
1991-12-13 |
2004-04-01 |
Xoma Corporation |
METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES.
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
DK1621554T4
(en)
|
1992-08-21 |
2012-12-17 |
Univ Bruxelles |
Immunoglobulins devoid of light chains
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
RU2170257C2
(en)
|
1994-03-17 |
2001-07-10 |
Мерк Патент Гмбх |
Anti-egfr single-chain fv, chimeric anti-egfr antibody and method of its preparing, pharmaceutical composition for treatment of patients with tumors, agent for diagnosis of localization and estimation of tumor growth
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US5773292A
(en)
|
1995-06-05 |
1998-06-30 |
Cornell University |
Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
DK0826696T3
(en)
|
1996-09-03 |
2002-09-23 |
Gsf Forschungszentrum Umwelt |
Use of bi- and trispecific antibodies to induce a tumor immunity
|
CN1203178C
(en)
|
1997-10-27 |
2005-05-25 |
尤尼利弗公司 |
Multivalent antigen-binding proteins
|
WO1999037681A2
(en)
|
1998-01-26 |
1999-07-29 |
Unilever Plc |
Method for producing antibody fragments
|
CZ121599A3
(en)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Single-chain molecule binding several antigens, process of its preparation and medicament in which the molecule is comprised
|
DK1144616T4
(en)
|
1999-01-19 |
2009-03-30 |
Unilever Nv |
Method for producing antibody fragments
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
US20060228364A1
(en)
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
EP1257632B1
(en)
|
2000-02-24 |
2007-09-12 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
CA2380443C
(en)
|
2000-05-26 |
2013-03-12 |
Ginette Dubuc |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
CN1294148C
(en)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
Single-stranded cyctic trispecific antibody
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
CN1195779C
(en)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
Double-specificity antibody resisting human ovary cancer and human CD3
|
US7666414B2
(en)
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
IL159225A0
(en)
|
2001-06-13 |
2004-06-01 |
Genmab As |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
US7371849B2
(en)
|
2001-09-13 |
2008-05-13 |
Institute For Antibodies Co., Ltd. |
Methods of constructing camel antibody libraries
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
ES2606537T3
(en)
|
2001-10-23 |
2017-03-24 |
Psma Development Company L.L.C. |
Antibodies against PSMA
|
JP2005289809A
(en)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
Mutant heavy-chain antibody
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
BR0307216A
(en)
|
2002-01-28 |
2005-12-20 |
Medarex Inc |
Human monoclonal antibodies to prostate specific membrane antigen (psma)
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
SI1517921T1
(en)
|
2002-06-28 |
2006-10-31 |
Domantis Ltd |
Dual specific ligands with increased serum half-life
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
CA2505515C
(en)
|
2002-11-07 |
2013-08-27 |
Erasmus Universiteit Rotterdam |
Fret probes and methods for detecting interacting molecules
|
CN102584997A
(en)
|
2002-11-08 |
2012-07-18 |
埃博灵克斯股份有限公司 |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
EP1558646A2
(en)
|
2002-11-08 |
2005-08-03 |
Ablynx N.V. |
Single domain antibodies directed against interferon- gamma and uses thereof
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
CA2505326A1
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
US8784821B1
(en)
|
2003-05-31 |
2014-07-22 |
Amgen Research (Munich) Gmbh |
Human-anti-human cd3 binding molecules
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
EP2272566A3
(en)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisation of antibodies
|
AU2004280333A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Llc |
Humanization of antibodies
|
CN100376599C
(en)
|
2004-04-01 |
2008-03-26 |
北京安波特基因工程技术有限公司 |
Recombining single chained three specific antibodies of anti CCA, anti CD 3, anti CD 28 through genetic engineering
|
EP2295588B1
(en)
|
2004-05-27 |
2018-03-07 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses thefor
|
EP1784427A2
(en)
|
2004-06-01 |
2007-05-16 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
EP1786918A4
(en)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
Novel tetravalent bispecific antibody
|
US20080069772A1
(en)
|
2004-08-26 |
2008-03-20 |
Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum |
Treatment of transformed or infected biological cells
|
EP1634603A1
(en)
|
2004-08-26 |
2006-03-15 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Treatment of transformed or infected biologic Cells
|
FR2879605B1
(en)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF THESE FORMATS
|
RS50752B
(en)
|
2005-01-05 |
2010-08-31 |
F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
US20060252096A1
(en)
|
2005-04-26 |
2006-11-09 |
Glycofi, Inc. |
Single chain antibody with cleavable linker
|
MX2007014359A
(en)
|
2005-05-18 |
2008-02-06 |
Ablynx Nv |
Improved nanobodies against tumor necrosis factor -alpha.
|
SI2444424T1
(en)
*
|
2005-05-20 |
2018-10-30 |
Ablynx N.V. |
Improved nanobodies tm for the treatment of aggregation-mediated disorders
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
BRPI0615026A8
(en)
|
2005-08-19 |
2018-03-06 |
Abbott Lab |
double variable domain immunoglobulin and its uses
|
JP5686953B2
(en)
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
Compositions comprising cross-species-specific antibodies and uses of the compositions
|
JP2009515878A
(en)
|
2005-11-12 |
2009-04-16 |
イーライ リリー アンド カンパニー |
Anti-EGFR antibody
|
US8623356B2
(en)
|
2005-11-29 |
2014-01-07 |
The University Of Sydney |
Demibodies: dimerization-activated therapeutic agents
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
US20110038854A1
(en)
|
2006-03-30 |
2011-02-17 |
University Of Medicine And Dentistry Of New Jersey |
Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
EP2057191A1
(en)
|
2006-08-18 |
2009-05-13 |
Ablynx N.V. |
Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
|
JP2010502208A
(en)
|
2006-09-08 |
2010-01-28 |
アブリンクス エン.ヴェー. |
Serum albumin binding protein with long half-life
|
US20100166734A1
(en)
|
2006-12-20 |
2010-07-01 |
Edward Dolk |
Oral delivery of polypeptides
|
AU2008234020B2
(en)
|
2007-04-03 |
2013-02-07 |
Amgen Research (Munich) Gmbh |
Cross-species-specific CD3-epsilon binding domain
|
CA2687903C
(en)
|
2007-05-24 |
2016-09-13 |
Ablynx N.V. |
Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
US9040666B2
(en)
|
2007-07-13 |
2015-05-26 |
Bac Ip B.V. |
Single-domain antigen-binding proteins that bind mammalian IgG
|
JP6035009B2
(en)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Activable binding polypeptides and methods for identification and use thereof
|
WO2009030285A1
(en)
|
2007-09-07 |
2009-03-12 |
Ablynx N.V. |
Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
|
EP2535351A3
(en)
*
|
2007-09-26 |
2013-04-03 |
UCB Pharma S.A. |
Dual specificity antibody fusions
|
SI2285408T1
(en)
|
2008-06-05 |
2019-02-28 |
Ablynx N.V. |
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
|
US20100122358A1
(en)
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
NZ590667A
(en)
|
2008-07-02 |
2013-01-25 |
Emergent Product Dev Seattle |
Tgf-b antagonist multi-target binding proteins
|
KR101820535B1
(en)
|
2008-10-01 |
2018-01-19 |
암젠 리서치 (뮌헨) 게엠베하 |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
WO2010037838A2
(en)
|
2008-10-01 |
2010-04-08 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
HRP20160857T4
(en)
|
2008-10-01 |
2022-12-09 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
EP2337798A4
(en)
*
|
2008-10-14 |
2012-10-24 |
Ca Nat Research Council |
Bsa-specific antibodies
|
US20100189727A1
(en)
|
2008-12-08 |
2010-07-29 |
Tegopharm Corporation |
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
|
BRPI1006141B8
(en)
|
2009-01-12 |
2021-05-25 |
Cytomx Therapeutics Llc |
modified antibody compositions, methods of making and using the same
|
EP2210902A1
(en)
|
2009-01-14 |
2010-07-28 |
TcL Pharma |
Recombinant monovalent antibodies
|
WO2010102251A2
(en)
|
2009-03-05 |
2010-09-10 |
Abbott Laboratories |
Il-17 binding proteins
|
UY32917A
(en)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
DLL-4 BINDING MOLECULES
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
RU2580038C2
(en)
|
2009-12-04 |
2016-04-10 |
Дженентек, Инк. |
Multispecific antibodies, thereof analogues, compositions and methods
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
LT2519543T
(en)
|
2009-12-29 |
2016-10-10 |
Emergent Product Development Seattle, Llc |
Heterodimer binding proteins and uses thereof
|
GB2476681B
(en)
|
2010-01-04 |
2012-04-04 |
Argen X Bv |
Humanized camelid VH, VK and VL immunoglobulin domains
|
EP2550529B1
(en)
|
2010-03-23 |
2021-11-17 |
Iogenetics, LLC. |
Bioinformatic processes for determination of peptide binding
|
US8937164B2
(en)
|
2010-03-26 |
2015-01-20 |
Ablynx N.V. |
Biological materials related to CXCR7
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
EP3336225B1
(en)
|
2010-07-16 |
2020-02-19 |
Adimab, LLC |
Antibody libraries
|
EP2603237A4
(en)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
RU2013110875A
(en)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
SPECIFIC ANTIBODIES CONTAINING DISSULPHIDE-STABILIZED Fv Fragment
|
EP2609112B1
(en)
|
2010-08-24 |
2017-11-22 |
Roche Glycart AG |
Activatable bispecific antibodies
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
JP2014500879A
(en)
|
2010-11-16 |
2014-01-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Factors and methods for treating diseases correlated with BCMA expression
|
KR20140018299A
(en)
*
|
2011-03-30 |
2014-02-12 |
아블린쓰 엔.브이. |
Methods of treating immune disorders with single domain antibodies against tnf-alpha
|
CN103596981B
(en)
|
2011-04-08 |
2017-06-16 |
美国卫生和人力服务部 |
Anti-epidermal growth factor receptor variant III Chimeric antigen receptors and its purposes for treating cancer
|
CN107903325B
(en)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
Multispecific FAB fusion proteins and methods of use thereof
|
BR112013028779B8
(en)
|
2011-05-27 |
2021-04-20 |
Glaxo Group Ltd |
antigen-binding protein or immunoconjugate, immunoconjugate, pharmaceutical composition, and, use of a composition
|
DK2723771T3
(en)
|
2011-06-23 |
2019-12-02 |
Ablynx Nv |
SERUM ALBUM BINDING PROTEINS
|
UA117901C2
(en)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Antibody variants and uses thereof
|
WO2013036130A1
(en)
|
2011-09-09 |
2013-03-14 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
CA2846436A1
(en)
|
2011-09-23 |
2013-03-28 |
Universitat Stuttgart |
Serum half-life extension using immunoglobulin binding domains
|
TWI679212B
(en)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
Binding molecules for e3 of bcma and cd3
|
AU2013208895B2
(en)
|
2012-01-13 |
2017-07-06 |
Julius-Maximilians-Universitat Wurzburg |
Dual antigen-induced bipartite functional complementation
|
EP2807189B1
(en)
|
2012-01-23 |
2019-03-20 |
Ablynx N.V. |
Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
|
EP2817318A4
(en)
|
2012-02-22 |
2016-04-27 |
Univ Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
SI2817338T1
(en)
|
2012-02-24 |
2017-11-30 |
Abbvie Stemcentrx Llc |
Dll3 modulators and methods of use
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
US20150037334A1
(en)
|
2012-03-01 |
2015-02-05 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
RU2014143639A
(en)
|
2012-03-30 |
2016-05-27 |
Байер Хелскеа Ллк |
ADJUSTABLE PROTEASIS ANTIBODIES
|
UA119227C2
(en)
|
2012-04-20 |
2019-05-27 |
Аптево Рісьорч Енд Девелопмент Ллс |
Cd3 binding polypeptides
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
CN103566377A
(en)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
Targeted immunotherapy for cancer
|
IN2015DN00138A
(en)
|
2012-08-31 |
2015-06-12 |
Argen X Bv |
|
KR101963231B1
(en)
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
Protein complex for preparing bispecific antibodies and method using thereof
|
JOP20200236A1
(en)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
|
CN104955845B
(en)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
Mesothelin antibody and cause the active method of effective antitumour
|
JO3519B1
(en)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
Antibody constructs for CDH19 and CD3
|
EP2964675B1
(en)
|
2013-03-05 |
2018-06-20 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
ES2746240T3
(en)
|
2013-03-13 |
2020-03-05 |
Health Research Inc |
Compositions and procedures for the use of recombinant T cell receptors for direct recognition of a tumor antigen
|
EP2970494B1
(en)
|
2013-03-14 |
2017-12-13 |
The Board of Regents of The University of Texas System |
Her3 specific monoclonal antibodies for diagnostic and therapeutic use
|
WO2014153002A1
(en)
|
2013-03-14 |
2014-09-25 |
The California Institute For Biomedical Research |
Bispecific antibodies and uses thereof
|
PL2970449T3
(en)
|
2013-03-15 |
2020-04-30 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
UY35459A
(en)
|
2013-03-15 |
2014-10-31 |
Bayer Healthcare Llc |
PROPHARM ANTIBODIES AGAINST THE INHIBITOR OF THE TISSULAR FACTOR ROAD
|
MX357011B
(en)
|
2013-03-15 |
2018-06-22 |
Amgen Inc |
Heterodimeric bispecific antibodies.
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
RS63152B1
(en)
|
2013-07-25 |
2022-05-31 |
Cytomx Therapeutics Inc |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
AU2014326972B2
(en)
|
2013-09-24 |
2020-10-29 |
University Of Washington Through Its Center For Commercialization |
Desmoglein 2 (DSG2) binding proteins and uses therefor
|
CN105814082A
(en)
|
2013-09-26 |
2016-07-27 |
埃博灵克斯股份有限公司 |
Bispecific nanobodies
|
EP3089994B1
(en)
|
2013-12-30 |
2022-05-04 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
AU2015237864B2
(en)
|
2014-03-24 |
2020-12-03 |
Cancer Research Technology Limited |
Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
|
WO2015146437A1
(en)
|
2014-03-25 |
2015-10-01 |
国立大学法人東北大学 |
HIGHLY-FUNCTIONAL IgG2 BISPECIFIC ANTIBODY
|
UA117289C2
(en)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Multispecific antibodies
|
IL286367B2
(en)
|
2014-05-02 |
2023-03-01 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
KR102355609B1
(en)
|
2014-05-29 |
2022-01-27 |
마크로제닉스, 인크. |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
EP3174903B1
(en)
|
2014-07-31 |
2024-04-10 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibody construct with enhanced tissue distribution
|
AR101669A1
(en)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
|
CN105471609B
(en)
|
2014-09-05 |
2019-04-05 |
华为技术有限公司 |
A kind of method and apparatus for configuration service
|
LT3189081T
(en)
|
2014-09-05 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Cd123 binding agents and uses thereof
|
EP3197916A2
(en)
|
2014-09-25 |
2017-08-02 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
KR20170068539A
(en)
|
2014-10-07 |
2017-06-19 |
셀렉티스 |
Method for modulating car-induced immune cells activity
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US10370435B2
(en)
|
2015-02-05 |
2019-08-06 |
Janssen Vaccines & Prevention B.V. |
Binding molecules directed against influenza hemagglutinin and uses thereof
|
US20180022819A1
(en)
|
2015-02-11 |
2018-01-25 |
Aptevo Research And Development Llc |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
BR112017022852A2
(en)
|
2015-04-22 |
2018-07-17 |
Agbiome Inc |
recombinant polypeptide with pesticidal activity, composition, recombinant nucleic acid molecule, recombinant nucleic acid, host cell, dna construct, vector, method for controlling a pest population, method for producing a polypeptide, plant, transgenic seed, method for protecting a plant and method for increasing yield in a plant
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
EP3296395B1
(en)
|
2015-05-13 |
2021-06-30 |
Chugai Seiyaku Kabushiki Kaisha |
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
US10526597B2
(en)
|
2015-05-21 |
2020-01-07 |
Full Spectrum Genetics, Inc. |
Method of improving characteristics of proteins
|
CN114805503A
(en)
|
2015-06-03 |
2022-07-29 |
农业生物群落股份有限公司 |
Insecticidal genes and methods of use
|
JP2018518972A
(en)
|
2015-06-26 |
2018-07-19 |
ユニバーシティ オブ サザン カリフォルニア |
Masking chimeric antigen receptor T cells for tumor specific activation
|
TWI796283B
(en)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for msln and cd3
|
TWI829617B
(en)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for flt3 and cd3
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
CN105384825B
(en)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
PE20180795A1
(en)
|
2015-08-17 |
2018-05-09 |
Janssen Pharmaceutica Nv |
ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND THE USE OF THEM
|
CN106519037B
(en)
|
2015-09-11 |
2019-07-23 |
科济生物医药(上海)有限公司 |
Activable Chimerical receptor
|
AU2016349482A1
(en)
|
2015-11-05 |
2018-05-24 |
City Of Hope |
Methods for preparing cells for adoptive T cell therapy
|
CN108289952B
(en)
|
2015-11-19 |
2021-02-05 |
雷维托普有限公司 |
Functional antibody fragment complementation of a two-component system for redirected killing of unwanted cells
|
UA126657C2
(en)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
Bcma and cd3 bispecific t cell engaging antibody constructs
|
CN108884126B
(en)
|
2016-02-03 |
2022-03-18 |
广州康睿生物医药科技股份有限公司 |
Compounds for treating eye disorders or diseases
|
CN105968201A
(en)
|
2016-02-03 |
2016-09-28 |
南昌大学 |
Single-domain heavy-chain antibody aiming at prostate specific membrane antigen
|
CN105968204B
(en)
|
2016-02-03 |
2020-01-21 |
中国人民解放军第三军医大学第一附属医院 |
Single-domain heavy chain antibody for resisting prostate specific membrane antigen
|
KR20230041739A
(en)
|
2016-03-08 |
2023-03-24 |
매버릭 테라퓨틱스, 인크. |
Inducible binding proteins and methods of use
|
CN109476756B
(en)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
Multi-specificity Fab fusion protein and application thereof
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
JP7042467B2
(en)
|
2016-05-20 |
2022-03-28 |
ハープーン セラピューティクス,インク. |
Single-chain variable fragment CD3 binding protein
|
CN109641047A
(en)
|
2016-05-20 |
2019-04-16 |
哈普恩治疗公司 |
Single domain seralbumin conjugated protein
|
US20190309092A1
(en)
|
2016-07-21 |
2019-10-10 |
Development Center For Biotechnology |
Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
|
CN109715668A
(en)
|
2016-08-02 |
2019-05-03 |
T细胞受体治疗公司 |
For using fusion protein to carry out the composition and method of TCR reprogramming
|
GB2564823B8
(en)
|
2016-10-07 |
2022-06-29 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR reprogramming using fusion proteins
|
US20190225702A1
(en)
|
2016-10-14 |
2019-07-25 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
WO2018083204A1
(en)
|
2016-11-02 |
2018-05-11 |
Engmab Sàrl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
WO2018098354A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
AU2017363302A1
(en)
|
2016-11-23 |
2019-06-27 |
Harpoon Therapeutics, Inc. |
PSMA targeting trispecific proteins and methods of use
|
WO2018136725A1
(en)
|
2017-01-19 |
2018-07-26 |
Harpoon Therapeutics, Inc. |
Innate immune cell inducible binding proteins and methods of use
|
WO2018133877A1
(en)
|
2017-01-23 |
2018-07-26 |
科济生物医药(上海)有限公司 |
Bcma-targeting antibody and use thereof
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
WO2018160671A1
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Targeted checkpoint inhibitors and methods of use
|
KR20190134654A
(en)
|
2017-03-09 |
2019-12-04 |
싸이톰스 테라퓨틱스, 인크. |
CD147 antibody, activatable CD147 antibody, and how to make and use it
|
EP3619234A4
(en)
|
2017-05-03 |
2021-05-26 |
Harpoon Therapeutics, Inc. |
Compositions and methods for adoptive cell therapies
|
EP3621994A4
(en)
|
2017-05-12 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
TWI757499B
(en)
|
2017-06-02 |
2022-03-11 |
美商輝瑞大藥廠 |
Antibodies specific for flt3 and their uses
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
CA3070539A1
(en)
|
2017-08-01 |
2019-02-07 |
Medimmune, Llc |
Bcma monoclonal antibody-drug conjugate
|
JP7151175B2
(en)
|
2017-09-15 |
2022-10-12 |
日本電産株式会社 |
transmission and actuator
|
WO2019075378A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
EA202090817A1
(en)
|
2017-10-13 |
2020-09-08 |
Харпун Терапьютикс, Инк. |
TRISSPECIFIC PROTEINS AND METHODS OF THEIR APPLICATION
|
WO2019222282A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Conditionally activated binding protein comprising a sterically occluded target binding domain
|
EP3794044A4
(en)
|
2018-05-14 |
2022-02-16 |
Harpoon Therapeutics, Inc. |
Dual binding moiety
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
BR112020024351A2
(en)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
binding molecules against bcma and uses thereof
|
WO2020060593A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Conditionally active receptors
|
US20220017626A1
(en)
|
2018-09-21 |
2022-01-20 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
WO2020061526A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
CN109593786A
(en)
|
2019-01-09 |
2019-04-09 |
上海怡豪生物科技有限公司 |
The double target spot CAR carriers and its construction method of joint EpCAM and MSLN single-chain antibody and in breast cancer application
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
WO2021097060A1
(en)
|
2019-11-13 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
Pro immune modulating molecule comprising a clustering moiety
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
Flt3 binding proteins and methods of use
|
WO2021231434A1
(en)
|
2020-05-12 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|